Literature DB >> 29505913

Occurrence of blaCMY-42 on an IncI1 plasmid in multidrug-resistant Escherichia coli from a tertiary referral hospital in India.

Birson Ingti1, Pranjit Saikia1, Deepjyoti Paul1, Anand Prakash Maurya1, Debadatta Dhar Chanda2, Atanu Chakravarty2, Chandrayee Deshamukhya1, Amitabha Bhattacharjee3.   

Abstract

OBJECTIVES: Plasmids of different replicon types are believed to be associated with the carriage and transmission of antimicrobial resistance genes. The present study was undertaken to examine the association of blaCIT with particular plasmid types and to identify Escherichia coli strains involve in the maintenance of this resistance determinant in the plasmid.
METHODS: Phenotypic screening of AmpC β-lactamases was performed by the modified three-dimensional extract method, followed by antimicrobial susceptibility testing and determination of minimum inhibitory concentrations (MICs). Genotyping screening of β-lactamase genes was performed by PCR assay, followed by sequencing. Transferability of the blaCMY gene was performed by transformation and conjugation experiments. Plasmid incompatibility typing and DNA fingerprinting by enterobacterial repetitive intergenic consensus (ERIC)-PCR were performed.
RESULTS: Among 203 E. coli obtained from different clinical specimens (pus, urine, stool and sputum), 37 were detected as harbouring the blaCIT gene and sequencing of this gene showed nucleotide sequence similarity with the blaCMY-42 variant. This study revealed IncI1-type plasmids as carriers of blaCMY-42 and its propagation within E. coli ST5377, ST361 and ST672. According to the stability results, the blaCMY-42-encoding plasmid can be maintained in E. coli strains for a longer duration without any antimicrobial pressure.
CONCLUSIONS: These finding document blaCMY-42 on IncI1-type plasmids, which are considered to be the main vehicles for the spread of blaCMY-42 in this hospital setting. Thus, a proper strategy should be developed to curb the expansion of IncI1-type plasmids in the hospital and community environment.
Copyright © 2018 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Escherichia coli; IncI1 plasmid; Multidrug-resistant; bla(CMY-42)

Mesh:

Substances:

Year:  2018        PMID: 29505913     DOI: 10.1016/j.jgar.2018.02.021

Source DB:  PubMed          Journal:  J Glob Antimicrob Resist        ISSN: 2213-7165            Impact factor:   4.035


  5 in total

1.  Phenotypic Identification and Genotypic Characterization of Plasmid-Mediated AmpC β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae Isolates in Iran.

Authors:  Saeedeh Robatjazi; Farhad Nikkhahi; Mojtaba Niazadeh; Seyed Mahmoud Amin Marashi; Amir Peymani; Amir Javadi; Amir Hossein Kashani
Journal:  Curr Microbiol       Date:  2021-04-10       Impact factor: 2.188

Review 2.  Incompatibility Group I1 (IncI1) Plasmids: Their Genetics, Biology, and Public Health Relevance.

Authors:  Steven L Foley; Pravin R Kaldhone; Steven C Ricke; Jing Han
Journal:  Microbiol Mol Biol Rev       Date:  2021-04-28       Impact factor: 11.056

3.  Acquisition of plasmid-mediated cephalosporinase producing Enterobacteriaceae after a travel to the tropics.

Authors:  Florian Lorme; Naouale Maataoui; Emilie Rondinaud; Marina Esposito-Farèse; Olivier Clermont; Etienne Ruppe; Guillaume Arlet; Nathalie Genel; Sophie Matheron; Antoine Andremont; Laurence Armand-Lefevre
Journal:  PLoS One       Date:  2018-12-18       Impact factor: 3.240

4.  Molecular characterization of Carbapenem resistant Escherichia coli recovered from a tertiary hospital in Lebanon.

Authors:  Christel Dagher; Tamara Salloum; Sahar Alousi; Harout Arabaghian; George F Araj; Sima Tokajian
Journal:  PLoS One       Date:  2018-09-06       Impact factor: 3.240

5.  Detection of CMY-type beta-lactamases in Escherichia coli isolates from paediatric patients in a tertiary care hospital in Mexico.

Authors:  Jocelin Merida-Vieyra; Agustín De Colsa-Ranero; Yair Calderón-Castañeda; Alejandra Aquino-Andrade
Journal:  Antimicrob Resist Infect Control       Date:  2020-10-29       Impact factor: 4.887

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.